ATE443160T1 - Für einen spannungsgesteuerten kaliumkanal kodierendes humanes adipositas- suszeptibilitätssgen und dessen verwendung - Google Patents

Für einen spannungsgesteuerten kaliumkanal kodierendes humanes adipositas- suszeptibilitätssgen und dessen verwendung

Info

Publication number
ATE443160T1
ATE443160T1 AT05764662T AT05764662T ATE443160T1 AT E443160 T1 ATE443160 T1 AT E443160T1 AT 05764662 T AT05764662 T AT 05764662T AT 05764662 T AT05764662 T AT 05764662T AT E443160 T1 ATE443160 T1 AT E443160T1
Authority
AT
Austria
Prior art keywords
obesity
voltage
gene encoding
susceptibility gene
potassium channel
Prior art date
Application number
AT05764662T
Other languages
English (en)
Inventor
Anne Philippi
Francis Rousseau
Elke Roschmann
Original Assignee
Integragen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integragen Sa filed Critical Integragen Sa
Application granted granted Critical
Publication of ATE443160T1 publication Critical patent/ATE443160T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Electrotherapy Devices (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05764662T 2004-06-14 2005-06-14 Für einen spannungsgesteuerten kaliumkanal kodierendes humanes adipositas- suszeptibilitätssgen und dessen verwendung ATE443160T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57882904P 2004-06-14 2004-06-14
PCT/IB2005/002356 WO2005123949A2 (en) 2004-06-14 2005-06-14 Human obesity susceptibility gene encoding a potassium voltage-gated channel and uses thereof

Publications (1)

Publication Number Publication Date
ATE443160T1 true ATE443160T1 (de) 2009-10-15

Family

ID=35395853

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05764662T ATE443160T1 (de) 2004-06-14 2005-06-14 Für einen spannungsgesteuerten kaliumkanal kodierendes humanes adipositas- suszeptibilitätssgen und dessen verwendung

Country Status (10)

Country Link
US (1) US20080193923A1 (de)
EP (1) EP1756316B1 (de)
JP (1) JP2008502341A (de)
AT (1) ATE443160T1 (de)
AU (1) AU2005254806B2 (de)
CA (1) CA2568957A1 (de)
DE (1) DE602005016676D1 (de)
DK (1) DK1756316T3 (de)
IL (1) IL179744A0 (de)
WO (1) WO2005123949A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113671179B (zh) * 2021-09-02 2023-10-03 中国科学院深圳先进技术研究院 一种kcnab2自身抗体的检测用试剂盒及其检测方法和应用
US20240417439A1 (en) * 2021-10-22 2024-12-19 The Hospital For Sick Children RECOMBINANT POLYPEPTIDE FOR DISRUPTING INTERACTION OF EAG2 AND KVß2 AND THERAPEUTIC APPLICATIONS THEREOF IN CANCER TREATMENT

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221900A (en) * 1991-04-30 1993-06-22 Hewlett-Packard Company Magnet structure for focusing of magnetic resonance images
US5252922A (en) * 1991-04-30 1993-10-12 Hewlett-Packard Company Radiofrequency focusing of magnetic resonance images
US5185573A (en) * 1991-04-16 1993-02-09 Hewlett-Packard Company Method for focusing of magnetic resonance images
US6477398B1 (en) * 1997-11-13 2002-11-05 Randell L. Mills Resonant magnetic susceptibility imaging (ReMSI)
AU2001245489A1 (en) * 2000-03-07 2001-09-17 Whitehead Institute For Biomedical Research Human single nucleotide polymorphisms
US6682888B1 (en) * 2000-05-05 2004-01-27 Incyte Corporation Genes expressed in alzheimer's disease
WO2002028999A2 (en) * 2000-10-03 2002-04-11 Gene Logic, Inc. Gene expression profiles in granulocytic cells
AU2003279980A1 (en) * 2002-10-16 2004-05-04 Incyte Corporation Transporters and ion channels

Also Published As

Publication number Publication date
IL179744A0 (en) 2007-05-15
AU2005254806A1 (en) 2005-12-29
DE602005016676D1 (de) 2009-10-29
WO2005123949A2 (en) 2005-12-29
JP2008502341A (ja) 2008-01-31
CA2568957A1 (en) 2005-12-29
WO2005123949A3 (en) 2006-03-16
DK1756316T3 (da) 2010-01-18
US20080193923A1 (en) 2008-08-14
AU2005254806B2 (en) 2009-06-04
EP1756316A2 (de) 2007-02-28
EP1756316B1 (de) 2009-09-16

Similar Documents

Publication Publication Date Title
Yang et al. Suboptimal treatment of diabetic peripheral neuropathic pain in the United States
Black et al. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study
Balikci et al. Adherence with outpatient appointments and medication: a two-year prospective study of patients with schizophrenia
Batta et al. IL-17 and-23 inhibitors for the treatment of psoriasis
WO2008070311A3 (en) Gene expression profiling of parkinson's disease
DE602005016676D1 (de) Für einen spannungsgesteuerten kaliumkanal kodierendes humanes adipositas-suszeptibilitätssgen und dessen verwendung
ATE382101T1 (de) Einen transkriptionsfaktor kodierendes humanes prädispositionsgen für autismus sowie dessen verwendungen
DK1504125T3 (da) Humant fedmemodtagelighedsgen og anvendelser deraf
ATE424469T1 (de) Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung
IL185868A0 (en) Human autism susceptibility gene encoding a transmembrane protein and uses thereof
WO2005021787A3 (en) Human obesity susceptibility gene and uses thereof
Penfold et al. Pediatric uptake of a newly available antipsychotic medication
WO2006087634A3 (en) Uses of human autism susceptibility gene encoding a kinase
Johnson Commercial viability of CNS drugs: Balancing the risk/reward profile
WO2005090600A3 (en) Human obesity susceptibility genes encoding peptide hormones and uses thereof
Makaryan et al. Clinical outcomes for patients with severe chronic neutropenia due to mutations in the gene for neutrophil elastase, ELANE
Kubarieva et al. Marketing investigation of preventive therapy of patients with multiple sclerosis
WO1999045112A3 (en) Chromosome 11-linked coronary heart disease susceptibility gene chd1
Wolthers et al. Common Genetic Variants in Trypsin Regulating Genes Are Associated with AsparAginase-Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Study
Chen et al. Development and validation of the Risk of Exacerbation in Severe Asthma (RESA) model
Nair et al. Erythropoetin (EPO) and granulocyte colony stimulating factor (GCS-F) based therapy in patients with low risk MDS: A single centre experience from India.
Clement et al. ID 242. Evaluation of Physical Activity Levels of Type II Diabetic Patients among the Public of Selangor, Malaysia.
Horner et al. Adherence to inhaled therapy and mortality in COPD
Damiati et al. AB1254-HPR Decoding the Association of Celiac Disease in Rheumatoid Arthritis Patients Using Clinical Risk Factors
Adams et al. Pain and comorbid psychiatric diagnoses among OEF/OIF returnees: evidence for a post-deployment multi-symptom disorder

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1756316

Country of ref document: EP

REN Ceased due to non-payment of the annual fee